The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering – standardized MSC products, optimized culture media, and cryopreservation solutions, the companies state.

“We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders,” says Lindsay Davies, CSO at NextCell.